Duration of Antibody Responses after Severe Acute Respiratory Syndrome
Open accessAbstract
Among 176 patients who had had severe acute respiratory syndrome (SARS), SARS-specific antibodies were maintained for an average of 2 years, and significant reduction of immunoglobulin G-positive percentage and titers occurred in the third year. Thus, SARS patients might be susceptible to reinfection >or=3 years after initial exposure.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Natural history studies suggest that SARS-CoV and MERS-CoV infections, particularly mild illnesses, may not generate long-lived antibody responses.
“This longitudinal assessment is relevant given that natural history studies suggest that SARS-CoV and MERS-CoV (Middle East respiratory syndrome coronavirus) infections, particularly mild illnesses, may not generate long-lived antibody responses.20-22”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [22]
The Study and Conclusions (pages not provided) support the SARS-CoV portion: antibody levels declined substantially by the third year after illness. This paper does not assess MERS-CoV or compare mild with more severe illness, so it does not support those parts of the cited sentence. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 14
- [1]Peiris JSM, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004; 10: S88– 97. 10.1038/nm1143 15577937 PMC7096017 · DOI
- [2]Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003; 302: 276– 9. 10.1126/science.1087139 12958366 · DOI
- [3]Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, Lei LC, Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005; 102: 2430– 5. 10.1073/pnas.0409608102 15695582 PMC548959 · DOI
- [4]Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310: 676– 9. 10.1126/science.1118391 16195424 · DOI
- [5]Lau SKP, Woo PCY, Li KSM, Huang Y, Tsoi HW, Wong BHL, Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005; 102: 14040– 5. 10.1073/pnas.0506735102 16169905 PMC1236580 · DOI
- [6]Wang L-F, Shi Z, Zhang S, Field H, Daszak P, Eaton BT. Review of bats and SARS. Emerg Infect Dis. 2006; 12: 1834– 40. 17326933 PMC3291347
- [7]Holmes KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest. 2003; 111: 1605– 9. 12782660 PMC156116
- [9]Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 2004; 190: 1119– 26. 10.1086/423286 15319862 PMC7199490 · DOI
- [10]Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006; 193: 792– 5. 10.1086/500469 16479513 PMC7109932 · DOI
- [11]Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006; 11: 49– 53. 10.1111/j.1440-1843.2006.00783.x 16423201 PMC7192223 · DOI
- [12]Woo PC, Lau SK, Wong BH, Chan KH, Chu CM, Tsoi HW, Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol. 2004; 11: 665– 8. 15242938 PMC440610
- [13]Chang SC, Wang JT, Huang LM, Chen YC, Fang CT, Sheng WH, Longitudinal analysis of severe acute respiratory syndrome (SARS) coronavirus-specific antibody in SARS patients. Clin Diagn Lab Immunol. 2005; 12: 1455– 7. 16339072 PMC1317065
- [14]Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005; 11: 411– 6. 15757556 PMC3298259
- [15]He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006; 176: 6085– 92. 16670317
Cited by
Sorted by citations
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
Popkin, B. M., Du, S., Green, W. D., Beck, M. A., Algaith, T., Herbst, C. H., Alsukait, R. F., Alluhidan, M., Alazemi, N., & Shekar, M. (2020) · Obesity Reviews · doi:10.1111/obr.13128 · Cited by 1,150 · see citing works
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120 · see citing works
Davies, N. G., Kucharski, A. J., Eggo, R. M., Gimma, A., Edmunds, W. J., Jombart, T., O'Reilly, K., Endo, A., Hellewell, J., Nightingale, E. S., et al. (2020) · The Lancet Public Health · doi:10.1016/s2468-2667(20)30133-x · Cited by 848 · see citing works
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015 · see citing works
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026 · see citing works
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.029 · Cited by 647 · see citing works
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586 · see citing works
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671 · see citing works
“Experience from other human coronaviruses has indicated the possibility of re-infection because of a waning antibody response (Callow et al., 1990; Wu et al., 2007).”
Immunological characteristics govern the transition of COVID-19 to endemicity
Lavine, J. S., Bjornstad, O. N., & Antia, R. (2021) · Science · doi:10.1126/science.abe6522 · Cited by 416 · see citing works
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496 · see citing works
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
Zuo, J., Dowell, A. C., Pearce, H., Verma, K., Long, H. M., Begum, J., Aiano, F., Amin-Chowdhury, Z., Hoschler, K., Brooks, T., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00902-8 · Cited by 392 · see citing works
Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K., & Perlman, S. (2014) · Journal of Virology · doi:10.1128/jvi.01505-14 · Cited by 411 · see citing works
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317 · see citing works
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
Baker, D., Roberts, C. A. K., Pryce, G., Kang, A. S., Marta, M., Reyes, S., Schmierer, K., Giovannoni, G., & Amor, S. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13495 · Cited by 192 · see citing works
Persistent cellular immunity to SARS-CoV-2 infection
Breton, G., Mendoza, P., Hägglöf, T., Oliveira, T. Y., Schaefer-Babajew, D., Gaebler, C., Turroja, M., Hurley, A., Caskey, M., & Nussenzweig, M. C. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202515 · Cited by 129 · see citing works
SARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada
Saeed, S., Drews, S. J., Pambrun, C., Yi, Q., Osmond, L., & O'Brien, S. F. (2021) · Transfusion · doi:10.1111/trf.16296 · Cited by 49 · see citing works
Li, C., Yu, D., Wu, X., Liang, H., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L., et al. (2021) · doi:10.1101/2021.04.05.437224 · Cited by 73 · see citing works
- Authors
- Wu, L.-P., Wang, N.-C., Chang, Y.-H., Tian, X.-Y., Na, D.-Y., Zhang, L.-Y., Zheng, L., Lan, T., Wang, L.-F., & Liang, G.-D.
- Affiliations
- Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, People’s Republic of China
- Shanxi Provincial People’s Hospital (CN)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- State Key Laboratory of Infectious Disease Prevention and Control (CN)
- Corresponding author
- Liang, Guo-Dong
- Venue
- Emerging Infectious Diseases
- Published
- 2007-10
- Volume
- 13
- Issue
- 10
- Pages
- 1562-1564
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- PMC
- PMC2851497
- OpenAlex
- W2151461700
- Cited by
- 426
- References
- 0
- Citations by year
- 2025: 3 · 2024: 12 · 2023: 28 · 2022: 51 · 2021: 152 · 2020: 169 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 2 · 2014: 1
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Emerging infectious diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Outbreaks Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS, antibody persistence, IgG, antibody titers, reinfection susceptibility, SARS-CoV
- MeSH terms
- Antibodies, Viral, Antibody Formation, China, Humans, Immunoglobulin G, Longitudinal Studies, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
